Abstract 159P
Background
To overcome the common Temozolomide (TMZ) resistance in Glioblastoma (GBM), targeting certain receptors such as GPCRs can be of benefit as they are involved in cancer treatment response signalling pathways. One attractive target is KISS1R, activated by Kisspeptin. RNA-Seq of male GBM samples revealed elevated KISS1R expression and low KISS1 expression, suggesting GBM as a paracrine tumour. By re-modulating KISS1R using exogenous kisspeptin (KP-10), we aimed to positively influence the cytotoxic effect of TMZ and investigate the underlying mechanism(s) in KISS1R-expressing GBM cells.
Methods
KISS1R expression was confirmed using RT-PCR. KP-10/TMZ IC50 was determined using MTT cell viability assay and synergistic combinations were analysed using Isobologram analysis with non-constant ratio. Pathway prediction was done using KEGG, Wikipathways and STITCH. Flow cytometry and live-cell imaging identified molecular mechanisms while relevant markers were assessed via JESS simple Westren. LC-MS/MS was used to identify relevant DEPs with Kaplan-Meier survival analysis to identify clinical relevance.
Results
KISS1R expression was confirmed in A-172 (p53 wild-type) and LN-18 (p53 mutant). KP-10/TMZ treatment demonstrated high synergism in both cells. Pathway analysis of KP-10/TMZ predicted interaction at apoptosis, cytoprotective autophagy and DNA damage. This was further confirmed with elevated autophagy marker p62 in A-172, while increased expression of DNA damage and repair markers PARP and γH2AX in LN-18. The proteomic profiles showed DEPs related to RNA splicing, cytoplasmic translation and ER stress in A-172, while negative regulation of mRNA, glycolysis and MHC class 1 protein binding in LN-18. Ten common DEPs impacted GBM patients’ survival.
Conclusions
The response to KP-10/TMZ treatment varied based on the status of p53 of the GBM cell used and commonly impacted DEPs associated with the cytoplasmic translation of proteins and regulation of mRNA, more seen in LN-18 (p53 mutant). This underscores the significance of delving into the concept of dormant cells within a single tumour to correlate the results from the in-vitro GBM model to actual GBM patients.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JCSMHS, Monash University Seed Grand and Monash Merit scholarship and funding for doctoral research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract